Press release
Metastatic Renal Cell Carcinoma Pipeline Assessment 2024: Clinical Trials, FDA Approvals, Therapies, ROA, MOA and Key Companies involved by DelveInsight | AstraZeneca, Genentech, Sumitomo Dainippon Pharma, Allogene Therapeutics, Nektar Therapeutics, Eli L
Metastatic Renal Cell Carcinoma Pipeline
Key Takeaways from the Metastatic Renal Cell Carcinoma Pipeline Report
• DelveInsight's Metastatic Renal Cell Carcinoma pipeline report depicts a robust space with 40+ active players working to develop 50+ pipeline therapies for Metastatic Renal Cell Carcinoma treatment.
• The leading companies working in the Metastatic Renal Cell Carcinoma Market include AstraZeneca, Genentech, Sumitomo Dainippon Pharma, Allogene Therapeutics, Nektar Therapeutics, Eli Lilly and Company, Xynomic Pharmaceuticals, AnewPharma, HUTCHMED, MedImmune, Incyte Corporation, NiKang Therapeutics, OncoC4, Inc., Nanobiotix, Aravive, Mirati Therapeutics Inc., BeiGene, Shanghai PerHum Therapeutics Co., Ltd., Akeso Biopharma, Novartis Pharmaceuticals, Vaccibody, SillaJen, Inc., Chongqing Precision Biotech Co. Ltd, Infinity Pharmaceuticals, Inc., SOTIO Biotech AG, Pfizer, Peloton Therapeutics, Inc., NeoTX Therapeutics Ltd, and others.
• Promising Metastatic Renal Cell Carcinoma Pipeline Therapies in the various stages of development include Nivolumab, Ipilimumab, Sunitinib, Pazopanib, Tc 99m EC20, AGS-16C3F, Axitinib, and others.
• December 2023: Ipsen announced a study of Phase 2 clinical trials for Cabozantinib. The overall objective of this study is to evaluate the efficacy and safety of cabozantinib as 2nd line treatment in subjects with unresectable, locally advanced or metastatic RCC with a clear-cell component, who progressed after prior Checkpoint Inhibitors (CPI) therapy with ipilimumab and nivolumab in combination or CPI combined with Vascular Endothelial Growth Factor (VEGF)-targeted therapy.
• December 2023: Hoffmann-La Roche announced a study of Phase 2 clinical trials for Tobemstomig, Tiragolumab, Pembrolizumab and Axitinib. This study will evaluate the efficacy, safety, and pharmacokinetics of tobemstomig (also known as RO7247669) in combination with axitinib alone or with tiragolumab (anti-TIGIT) and axitinib, as compared to pembrolizumab and axitinib in participants with previously untreated, unresectable locally advanced or metastatic clear-cell renal cell carcinoma (ccRCC).
Request a sample and discover the recent advances in Metastatic Renal Cell Carcinoma Treatment Drugs @ Metastatic Renal Cell Carcinoma Pipeline Outlook Report- https://www.delveinsight.com/report-store/metastatic-renal-cell-carcinoma-mrcc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
In the Metastatic Renal Cell Carcinoma pipeline report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, Metastatic Renal Cell Carcinoma NDA approvals (if any), and product development activities comprising the technology, Metastatic Renal Cell Carcinoma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Metastatic Renal Cell Carcinoma Overview
Renal cell carcinoma is the most common type of kidney cancer in adults. It accounts for approximately 85% of neoplasms arising from the kidney. Renal cell carcinoma may remain clinically occult for most of its course. Only 10% of patients present with the classic triad of flank pain, hematuria, and flank mass. Patients with renal cell cancer (RCC) develop metastatic spread in approximately 33% of cases.
Find out more about Metastatic Renal Cell Carcinoma Therapeutics Assessment @ Metastatic Renal Cell Carcinoma Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/metastatic-renal-cell-carcinoma-mrcc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Metastatic Renal Cell Carcinoma Emerging Drugs Profile
• Olaparib: AstraZeneca
• Atezolizumab: Genentech
• TP-1454: Sumitomo Dainippon Pharma
Metastatic Renal Cell Carcinoma Pipeline Therapeutics Assessment
There are approx. 40+ key companies which are developing the Metastatic Renal Cell Carcinoma therapies. The Metastatic Renal Cell Carcinoma companies which have their Metastatic Renal Cell Carcinoma drug candidates in the most advanced stage, i.e. phase III include, Genentech.
DelveInsight's Metastatic Renal Cell Carcinoma pipeline report covers around 50+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Metastatic Renal Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous
Metastatic Renal Cell Carcinoma Products have been categorized under various Molecule types such as
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine
Learn more about the emerging Metastatic Renal Cell Carcinoma Pipeline Therapies @ Metastatic Renal Cell Carcinoma Clinical Trials Assessment- https://www.delveinsight.com/sample-request/metastatic-renal-cell-carcinoma-mrcc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Metastatic Renal Cell Carcinoma Pipeline Report
• Coverage- Global
• Metastatic Renal Cell Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Metastatic Renal Cell Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Metastatic Renal Cell Carcinoma Companies- AstraZeneca, Genentech, Sumitomo Dainippon Pharma, Allogene Therapeutics, Nektar Therapeutics, Eli Lilly and Company, Xynomic Pharmaceuticals, AnewPharma, HUTCHMED, MedImmune, Incyte Corporation, NiKang Therapeutics, OncoC4, Inc., Nanobiotix, Aravive, Mirati Therapeutics Inc., BeiGene, Shanghai PerHum Therapeutics Co., Ltd., Akeso Biopharma, Novartis Pharmaceuticals, Vaccibody, SillaJen, Inc., Chongqing Precision Biotech Co. Ltd, Infinity Pharmaceuticals, Inc., SOTIO Biotech AG, Pfizer, Peloton Therapeutics, Inc., NeoTX Therapeutics Ltd, and others.
• Metastatic Renal Cell Carcinoma Pipeline Therapies- Nivolumab, Ipilimumab, Sunitinib, Pazopanib, Tc 99m EC20, AGS-16C3F, Axitinib, and others.
Dive deep into rich insights for new drugs for Metastatic Renal Cell Carcinoma Treatment, Visit @ Metastatic Renal Cell Carcinoma Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/metastatic-renal-cell-carcinoma-mrcc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Content
1. Introduction
2. Executive Summary
3. Metastatic Renal Cell Carcinoma: Overview
4. Metastatic Renal Cell Carcinoma Pipeline Therapeutics
5. Metastatic Renal Cell Carcinoma Therapeutic Assessment
6. Metastatic Renal Cell Carcinoma - DelveInsight's Analytical Perspective
7. Late Stage Metastatic Renal Cell Carcinoma Products (Phase III)
8. Atezolizumab: Genentech
9. Drug profiles in the detailed report…..
10. Mid-Stage Metastatic Renal Cell Carcinoma Products (Phase II)
11. Olaparib: AstraZeneca
12. Drug profiles in the detailed report…..
13. Early Stage Metastatic Renal Cell Carcinoma Products (Phase I)
14. TP-1454: Sumitomo Dainippon Pharma
15. Drug profiles in the detailed report…..
16. Metastatic Renal Cell Carcinoma Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Metastatic Renal Cell Carcinoma Key Companies
21. Metastatic Renal Cell Carcinoma Key Products
22. Metastatic Renal Cell Carcinoma Unmet Needs
23. Metastatic Renal Cell Carcinoma Market Drivers and Barriers
24. Metastatic Renal Cell Carcinoma- Future Perspectives and Conclusion
25. Metastatic Renal Cell Carcinoma Analyst Views
26. Metastatic Renal Cell Carcinoma Key Companies
27. Appendix
For further information on the Metastatic Renal Cell Carcinoma Pipeline therapeutics, reach out to Metastatic Renal Cell Carcinoma Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/metastatic-renal-cell-carcinoma-mrcc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Trending Reports:
• Abetalipoproteinemia Market: https://www.delveinsight.com/report-store/abetalipoproteinemia-market
• Polycythemia Market: https://www.delveinsight.com/report-store/polycythemia-vera-market
• Ambulatory Arrhythmia Monitoring Devices Market: https://www.delveinsight.com/report-store/ambulatory-arrhythmia-monitoring-devices-market
• Choroidal Neovascularization Market: https://www.delveinsight.com/report-store/choroidal-neovascularization-market
• Pruritus Market: https://www.delveinsight.com/report-store/pruritus-market
• Cardiopulmonary Bypass Equipment Market: https://www.delveinsight.com/report-store/cardiopulmonary-bypass-equipment-market
• Chemotherapy Induced Anemia Market: https://www.delveinsight.com/report-store/chemotherapy-induced-anemia-market
• Chronic Bronchitis Market: https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-market
• Clbp Market: https://www.delveinsight.com/report-store/chronic-lower-back-pain-clbp-market
• Hearing Implants Market: https://www.delveinsight.com/report-store/hearing-implants-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Pemphigus Vulgaris Market: https://www.delveinsight.com/infographics/pemphigus-vulgaris-market
• Polycythemia Vera Market: https://www.delveinsight.com/report-store/polycythemia-vera-market
• Advanced Renal Cell Carcinoma Market: https://www.delveinsight.com/report-store/advanced-renal-cell-carcinoma-rcc-market
• Airway Stent Market Market: https://www.delveinsight.com/report-store/airway-stent-market
• Allergic Conjunctivitis Market: https://www.delveinsight.com/report-store/allergic-conjunctivitis-market
• Alopecia Areata Market: https://www.delveinsight.com/report-store/alopecia-areata-market
• Alport Syndrome Market: https://www.delveinsight.com/report-store/alport-syndrome-market
• Angioedema Market: https://www.delveinsight.com/report-store/angioedema-market
• Bladder Pain Syndrome Market: https://www.delveinsight.com/report-store/interstitial-cystitis-market
• Bone Densitometers Market: https://www.delveinsight.com/report-store/bone-densitometers-market
• Brain Aneurysm Stents Market: https://www.delveinsight.com/report-store/brain-aneurysm-stents-market
• Calciphylaxis Market: https://www.delveinsight.com/report-store/calciphylaxis-market
• Chronic Inflammatory Demyelinating Polyneuropathy Market: https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market
• Chronic Inflammtory Demyelinating Polyneuropathy Market: https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market
• Chronic Myelogenous Leukemia Market: https://www.delveinsight.com/report-store/chronic-myeloid-leukemia-market
• Cutaneous T-cell Lymphoma Market: https://www.delveinsight.com/report-store/cutaneous-t-cell-lymphoma-ctcl-market
• Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Dermal Erythema Market: https://www.delveinsight.com/report-store/dermal-erythema-market
• Eczema Market: https://www.delveinsight.com/report-store/atopic-dermatitis-market
Contact Info:
Ankit Nigam
Manager (Marketing & Branding)
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Metastatic Renal Cell Carcinoma Pipeline Assessment 2024: Clinical Trials, FDA Approvals, Therapies, ROA, MOA and Key Companies involved by DelveInsight | AstraZeneca, Genentech, Sumitomo Dainippon Pharma, Allogene Therapeutics, Nektar Therapeutics, Eli L here
News-ID: 3472611 • Views: …
More Releases from DelveInsight Business Research
Vitiligo Competitive Landscape 2025: Clinical Trial Analysis, Therapies, FDA App …
The "Vitiligo Pipeline Insight, 2025" report by DelveInsight delivers an in-depth view of the current clinical development scenario along with the future growth trajectory of the Vitiligo Market.
As per DelveInsight's evaluation, the global Vitiligo treatment pipeline features 20+ leading companies actively engaged in developing 20+ therapeutic candidates. The analysis covers Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and developmental updates.
The Vitiligo Pipeline report offers extensive commercial and clinical…
Myelodysplastic Syndrome Competitive Landscape 2025: Clinical Trial Analysis, Th …
DelveInsight's, "Myelodysplastic Syndrome Pipeline Insight 2025" report provides comprehensive insights about 120+ companies and 150+ pipeline drugs in Myelodysplastic Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Myelodysplastic Syndrome Pipeline Report
• DelveInsight's Myelodysplastic Syndrome…
Fibromyalgia Competitive Landscape 2025: Clinical Trial Analysis, Therapies, FDA …
According to DelveInsight, the global Fibromyalgia pipeline features more than eight key companies actively developing over ten treatment candidates. The analysis encompasses ongoing clinical trials, therapeutic mechanisms of action, routes of administration, and recent developments within the Fibromyalgia treatment landscape.
The Fibromyalgia Pipeline 2025 report provides an exhaustive evaluation of pipeline products, ranging from preclinical stages to marketed therapies. It includes comprehensive details on each drug's mechanism of action, clinical trial…
Chronic Wounds Competitive Landscape 2025: Clinical Trial Analysis, Therapies, F …
As per DelveInsight's assessment, globally, Chronic Wounds pipeline constitutes 7+ key companies continuously working towards developing 8+ Chronic Wounds treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Chronic Wounds Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Wounds Market.
The Chronic Wounds Pipeline report embraces in-depth commercial and clinical assessment…
More Releases for Renal
Advancements in Renal Dialysis Equipment Trend: A Crucial Influence on the Renal …
What market dynamics are playing a key role in accelerating the growth of the renal dialysis equipment market?
The escalating incidence of chronic kidney disease is projected to boost the expansion of the renal dialysis equipment market. Chronic kidney disease, a term that describes the slow and progressive decline of kidney function, can ultimately result in kidney failure and other severe health conditions. This disease is linked with several risk factors…
Renal Osteodystrophy Market: An In-Depth Analysis
The Renal Osteodystrophy Market was valued at approximately USD 2.4 billion in 2023 and is projected to reach around USD 7.1 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 12.5% from 2024 to 2032.
Renal Osteodystrophy Market Overview
The Renal Osteodystrophy Market is experiencing significant growth, driven by the increasing prevalence of chronic kidney disease (CKD) and the associated bone disorders. Advancements in diagnostic techniques have enhanced early…
Shaping the Renal Dialysis Equipment Market in 2025: Advancements in Renal Dialy …
How Big Is the Renal Dialysis Equipment Market Expected to Be, and What Will Its Growth Rate Be?
In recent years, the renal dialysis equipment market has seen robust growth. It's projected to increase from $19.52 billion in 2024 to $20.92 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 7.2%. Factors contributing to growth in the historic period include comprehensive training and support programs, substantial research and development…
Transforming the Veterinary Renal Disease Market in 2025: Increasing Pet Ownersh …
"What Is the Expected Size and Growth Rate of the Veterinary Renal Disease Market?
The market size for veterinary kidney diseases has seen profound growth recently. It is set to expand from $15.5 billion in 2024 to $16.63 billion in 2025, with a compound annual growth rate (CAGR) of 7.3%. Several factors contributed to this growth during the historical period, including heightened initiatives to increase disease awareness, a shift in…
Renal Cancer Pipeline Outlook Report 2024
DelveInsight's, "Renal Cancer Pipeline Insight 2024" report provides comprehensive insights about 75+ Renal Cancer companies and 80+ pipeline drugs in the Renal Cancer pipeline landscape. It covers the Renal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Renal Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways…
Renal Biomarker Market to register a CAGR of 7.0% by 2026: Rising Prevalence of …
Future Market Insights delivers key insights on the global renal biomarker market in a new report titled “Renal Biomarker Market: Global Industry Analysis and Opportunity Assessment, 2016–2026.” In terms of revenue, the global renal biomarker market is projected to register a healthy CAGR of 7.0% over the forecast period. In this report, Future Market Insights throws light on the various factors and trends impacting market growth over the forecast period…
